A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Merck

Protocol Number
MK-3475-181

To Learn More Call
201-510-0910

A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Georgetown

Protocol Number
2011-384

To Learn More Call
201-510-0910

Testing Spectrosense EVA system for detection of pancreatic cancer by analyzing Volatile Organic Compounds (VOCs) in exhaled air

Type of Cancer
Gastrointestinal

Site
Hackensack

Sponsor
Spectrosense Ltd.

Protocol Number
Spectrosense EVA Protocol PAC

To Learn More Call
201-510-0910